Livongo Health closed a $105 million round led by a group of investors including General Catalyst, Merck Global Health Innovation Fund and Echo Health Ventures.
The Mountain View, Calif.-based company has developed Livongo for Diabetes – a collection of connected devices that enable people with diabetes to interact with a virtual care team.
“We are particularly pleased with the strong vote of confidence from the marketplace for Livongo,” CEO Glen Tullman said in prepared remarks.
Livongo also inked a strategic partnership with Cambia Health Solutions, a nonprofit health insurance company based in Oregon.
“The solutions we build with Cambia will reflect our shared perspective that we need to address the whole person comprehensively. This approach is gaining traction in the market, in large part based on our industry-leading member satisfaction, proven clinical and financial outcomes,” Tullman added.
Livongo plans to use its newly-acquired funds to support market growth and its consumer platform. The company is also launching a disease management offering for people with hypertension.
“Livongo has become the market leader by providing a delightful, evidence-based approach for improving quality of life for consumers with diabetes,” Hemant Taneja, managing director at General Catalyst, said.
In September last year, Livongo bought Diabeto and its suite of connective tech, for an undisclosed amount. Diabeto sells a device called Birdie that plugs into more than 40 different glucose meters, connecting them to mobile diabetes management apps.
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn